Pfizer Inc (PFE)

$25.09 +0.06 (0.24%)
Market Cap 142.65B
Revenue (ttm) 63.63B
Net Income (ttm) 8.03B
EPS (ttm) N/A
PE Ratio 7.82
Forward PE 8.02
Profit Margin 12.62%
Debt to Equity Ratio 0.66
Volume 21,617,800
Avg Vol 68,387,570
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 14%
Beta 0.46
Analysts Sell
Price Target $27.95

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and tre...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
HoodyHaz
HoodyHaz Dec. 28 at 7:16 PM
$ALT I believe we had a “Final 3” in negotiations.. Pfizer was kicked out $PFE …. Now Nove Nordisk (makers of Ozempic)$NVO Is back at the table to get the blockbuster drug of the decade in ”Pemvidutide” .. However, I believe some company has the fight of first refusal, upon the de-risking of the PH 2 and agreement of Ph3 design with FDA.. That ph3 design comes the same day as Ph2 eom from Fda… (just like it did in Nov 2024 for obesity ).. Prior to… Shorts will buy their shares back up to the $15 mark …BUYOUT swiftly after… at $150 per share 10x is ok for buyout price… Todays 40x is not.. KNOW WHAT YOU OWN..
1 · Reply
Crash_Bash
Crash_Bash Dec. 28 at 7:07 PM
$SGMO $SGMO last year on Dec 30th, we got the crushing news of $PFE breaking up with sgmo. Im hoping this time we have a better news in those last few days of Dec.
2 · Reply
Longbuy1
Longbuy1 Dec. 28 at 5:52 PM
$SLS $PFE $MRK $ABBV are all going to want GPS - SLS combo drug treatment, a bidding war is very possible. What we do know is that the CEO from $PFE has tried to set up a meeting with Angelos. This will hit 5$ a share before the readout, then FDA will accelerate approval, another sharp rise in stock price. Then the bidding wars start. Your sitting on the best breakout stock of 2026. $GME maybe even a meme stock which a solid pipeline and none of this is even taking into consideration SLS performed much much better then expected in its phase 2 study.
0 · Reply
Muskvoice
Muskvoice Dec. 28 at 2:48 PM
$ALT $NVO $GILD $PFE $SNY Speculated Acquirers from Investor Discussions and AnalysesThese are based on retail investor chatter (e.g., on X/Twitter and Reddit), analyst notes, and sector trends, often citing $ALT's undervalued market cap (~$400M as of late 2025), strong Phase 2 data, and need for funding ahead of Phase 3 trials. Many predict a deal or partnership in Q1 2026.Sanofi (SNY): Frequently cited as a logical fit due to $ALT CEO Jerry Durso's 22-year history at Sanofi, which could facilitate a smooth integration. Speculation includes a "subsidiary model" acquisition (similar to Sanofi's Genzyme deal) to preserve $ALT's clinical momentum without big pharma bureaucracy. Sanofi has been active in metabolic disease deals.
0 · Reply
JuggernautRaider
JuggernautRaider Dec. 28 at 1:49 PM
$ALT top potential acquirers: 1. Eli Lilly (LLY) Best strategic fit. Lilly dominates obesity/metabolic disease and continues to invest aggressively to defend leadership. Pemvidutide’s dual GLP-1/glucagon mechanism and strong Phase 2b MASH data would complement Lilly’s incretin portfolio and extend reach into liver disease. 2. Novo Nordisk $NVO Clear incentive to neutralize emerging competition. Novo leads GLP-1s but lacks a differentiated MASH asset with antifibrotic signals. ALT would add pipeline depth and protect Novo’s long-term metabolic franchise. 3. Gilead Sciences $GILD Historically strong in liver disease and actively rebuilding growth. Pemvidutide’s MASH data directly aligns with Gilead’s strategic focus, and ALT’s market cap is easily digestible for GILD. 4. Pfizer $PFE Capital-rich and motivated to rebuild its post-COVID pipeline. Pfizer has publicly emphasized obesity and metabolic disease as priority areas, making ALT a logical bolt-on acquisition.
4 · Reply
gumby2196
gumby2196 Dec. 28 at 5:36 AM
$PFE is loosing the monthly 5 MAs again.
1 · Reply
reyofhope
reyofhope Dec. 28 at 5:03 AM
$PFE why are we trending?
1 · Reply
taxplanr
taxplanr Dec. 28 at 4:02 AM
DNA found in all C19 jabs $BNTX $MRNA $PFE https://www.instagram.com/reel/DSvhgVgEnE3/?igsh=MWcxcW11YzV4NmFwcQ==
0 · Reply
hegdaom
hegdaom Dec. 28 at 4:01 AM
$AGIO $LLY $PFE $MRK $CRSP
1 · Reply
taxplanr
taxplanr Dec. 28 at 3:52 AM
Complete investigation and accountability of the CDC $BNTX $MRNA $PFE https://www.instagram.com/p/DSu4_B3lZYS/?img_index=1&igsh=MWl6cWVyZTh1emNoOQ==
0 · Reply
Latest News on PFE
Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

Dec 26, 2025, 10:35 PM EST - 1 day ago

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

CVX KMB ABM ABT AMGN AVGO BCPC

Pfizer says patient dies after receiving hemophilia drug in trial

Dec 23, 2025, 11:24 AM EST - 5 days ago

Pfizer says patient dies after receiving hemophilia drug in trial

Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound

Dec 19, 2025, 11:45 AM EST - 9 days ago

Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound

Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 9 days ago

Trump to announce new drug-pricing deals later today

ABBV AMGN AZN BMY GILD LLY MRK

Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

Dec 18, 2025, 10:00 AM EST - 10 days ago

Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun

Dec 18, 2025, 6:58 AM EST - 10 days ago

Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun

AbbVie, several other pharma companies near MFN deal with Trump, sources say

Dec 17, 2025, 4:11 PM EST - 11 days ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

ABBV AMGN AZN BMY LLY NVS

Pfizer Stock Can Sink More. Here Is How

Dec 17, 2025, 2:36 PM EST - 11 days ago

Pfizer Stock Can Sink More. Here Is How

Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back

Dec 17, 2025, 10:14 AM EST - 11 days ago

Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back

MRK

PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Dec 17, 2025, 6:45 AM EST - 11 days ago

PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript

Dec 16, 2025, 2:39 PM EST - 12 days ago

Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript

Pfizer falls on disappointing guidance

Dec 16, 2025, 12:33 PM EST - 12 days ago

Pfizer falls on disappointing guidance

Pfizer's modest 2026 outlook shows its big investments will take time to pay off

Dec 16, 2025, 10:12 AM EST - 12 days ago

Pfizer's modest 2026 outlook shows its big investments will take time to pay off

Here's why Pfizer is revising its revenue forecasts

Dec 16, 2025, 7:47 AM EST - 12 days ago

Here's why Pfizer is revising its revenue forecasts

Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales.

Dec 16, 2025, 7:25 AM EST - 12 days ago

Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales.

Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings

Dec 16, 2025, 7:16 AM EST - 12 days ago

Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings

Pfizer forecasts 2026 profit below expectations on lower COVID product sales

Dec 16, 2025, 6:54 AM EST - 12 days ago

Pfizer forecasts 2026 profit below expectations on lower COVID product sales

Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance

Dec 16, 2025, 6:45 AM EST - 12 days ago

Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance

Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million

Dec 15, 2025, 8:24 AM EST - 13 days ago

Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million

ADPT

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

Dec 15, 2025, 8:00 AM EST - 13 days ago

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

ADPT

Pfizer Declares First-Quarter 2026 Dividend

Dec 12, 2025, 12:00 PM EST - 16 days ago

Pfizer Declares First-Quarter 2026 Dividend

Dividend Harvesting Portfolio Week 249: $24,900 Allocated, $2,646.53 In Projected Dividends

Dec 12, 2025, 8:45 AM EST - 16 days ago

Dividend Harvesting Portfolio Week 249: $24,900 Allocated, $2,646.53 In Projected Dividends

AMLP MO MSTY OHI

Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial

Dec 12, 2025, 7:24 AM EST - 16 days ago

Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial

Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports

Dec 10, 2025, 11:38 AM EST - 18 days ago

Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

Dec 10, 2025, 8:15 AM EST - 18 days ago

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

Will Pfizer's YaoPharma deal deliver a powerful new oral obesity pill?

Dec 9, 2025, 3:30 PM EST - 19 days ago

Will Pfizer's YaoPharma deal deliver a powerful new oral obesity pill?

Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill

Dec 9, 2025, 11:14 AM EST - 19 days ago

Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill

Undisclosed Deaths in the Pfizer mRNA COVID-19 Vaccine Trial Discussed in the Journal of American Physicians and Surgeons

Dec 9, 2025, 10:59 AM EST - 19 days ago

Undisclosed Deaths in the Pfizer mRNA COVID-19 Vaccine Trial Discussed in the Journal of American Physicians and Surgeons

Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains

Dec 9, 2025, 10:45 AM EST - 19 days ago

Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains

Here's 12 Ideal 'Safer' December Dividend Dogs Of The S&P500

Dec 9, 2025, 10:15 AM EST - 19 days ago

Here's 12 Ideal 'Safer' December Dividend Dogs Of The S&P500

AES AMCR ARE CAG CPB D DOC

Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement

Dec 9, 2025, 6:55 AM EST - 19 days ago

Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement

Pfizer partners with YaoPharma for weight management treatment

Dec 9, 2025, 6:38 AM EST - 19 days ago

Pfizer partners with YaoPharma for weight management treatment

Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma

Dec 9, 2025, 6:30 AM EST - 19 days ago

Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

Dec 6, 2025, 5:15 PM EST - 21 days ago

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

Pfizer: The Market Is Still Wrong About It

Dec 5, 2025, 9:00 AM EST - 23 days ago

Pfizer: The Market Is Still Wrong About It

17 dividend-stock bargains from a value manager with a stellar track record

Dec 2, 2025, 12:11 PM EST - 26 days ago

17 dividend-stock bargains from a value manager with a stellar track record

BMY CIVI CMCSA CVS MOS MRK MTH

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

Dec 1, 2025, 3:50 PM EST - 27 days ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

BNTX MRNA NVAX

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Dec 1, 2025, 12:35 PM EST - 27 days ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

BNTX MRNA NVAX

Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance

Dec 1, 2025, 10:00 AM EST - 27 days ago

Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance

Pfizer: The Patent Cloud Is An Opportunity For Bargain Hunters

Nov 30, 2025, 6:13 AM EST - 4 weeks ago

Pfizer: The Patent Cloud Is An Opportunity For Bargain Hunters

Pfizer, Mastercard Among 24 Companies To Announce Annual Increases In December

Nov 29, 2025, 11:59 PM EST - 4 weeks ago

Pfizer, Mastercard Among 24 Companies To Announce Annual Increases In December

MA AVGO

8 'Safer' Dividend Buys In Barron's 23 Better November Bets Than T-Bills

Nov 28, 2025, 11:00 AM EST - 4 weeks ago

8 'Safer' Dividend Buys In Barron's 23 Better November Bets Than T-Bills

BBB BBY BMY CAG EQR KEY KIM

Final Trade: DAL, AXP, PFE, HMY

Nov 26, 2025, 6:20 PM EST - 4 weeks ago

Final Trade: DAL, AXP, PFE, HMY

AXP DAL HMY

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

Nov 26, 2025, 12:30 PM EST - 4 weeks ago

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

VALN

JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?

Nov 25, 2025, 5:20 AM EST - 4 weeks ago

JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?

JNJ

U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer

Nov 21, 2025, 1:24 PM EST - 5 weeks ago

U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer

Pfizer Crosses Below Key Moving Average Level

Nov 20, 2025, 4:05 PM EST - 5 weeks ago

Pfizer Crosses Below Key Moving Average Level

$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield

Nov 20, 2025, 11:17 AM EST - 5 weeks ago

$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield

AMGN BMY GILD IVV MRK SPY VOO

October Readers Identified 10 Ideal "Safer" Dividends In 39 Dogs

Nov 19, 2025, 5:43 PM EST - 5 weeks ago

October Readers Identified 10 Ideal "Safer" Dividends In 39 Dogs

CAG CIM EPD HAFN HRL IPG KEY

Pfizer: Is This Pharma Giant Finally A Bargain

Nov 19, 2025, 3:51 PM EST - 5 weeks ago

Pfizer: Is This Pharma Giant Finally A Bargain

HoodyHaz
HoodyHaz Dec. 28 at 7:16 PM
$ALT I believe we had a “Final 3” in negotiations.. Pfizer was kicked out $PFE …. Now Nove Nordisk (makers of Ozempic)$NVO Is back at the table to get the blockbuster drug of the decade in ”Pemvidutide” .. However, I believe some company has the fight of first refusal, upon the de-risking of the PH 2 and agreement of Ph3 design with FDA.. That ph3 design comes the same day as Ph2 eom from Fda… (just like it did in Nov 2024 for obesity ).. Prior to… Shorts will buy their shares back up to the $15 mark …BUYOUT swiftly after… at $150 per share 10x is ok for buyout price… Todays 40x is not.. KNOW WHAT YOU OWN..
1 · Reply
Crash_Bash
Crash_Bash Dec. 28 at 7:07 PM
$SGMO $SGMO last year on Dec 30th, we got the crushing news of $PFE breaking up with sgmo. Im hoping this time we have a better news in those last few days of Dec.
2 · Reply
Longbuy1
Longbuy1 Dec. 28 at 5:52 PM
$SLS $PFE $MRK $ABBV are all going to want GPS - SLS combo drug treatment, a bidding war is very possible. What we do know is that the CEO from $PFE has tried to set up a meeting with Angelos. This will hit 5$ a share before the readout, then FDA will accelerate approval, another sharp rise in stock price. Then the bidding wars start. Your sitting on the best breakout stock of 2026. $GME maybe even a meme stock which a solid pipeline and none of this is even taking into consideration SLS performed much much better then expected in its phase 2 study.
0 · Reply
Muskvoice
Muskvoice Dec. 28 at 2:48 PM
$ALT $NVO $GILD $PFE $SNY Speculated Acquirers from Investor Discussions and AnalysesThese are based on retail investor chatter (e.g., on X/Twitter and Reddit), analyst notes, and sector trends, often citing $ALT's undervalued market cap (~$400M as of late 2025), strong Phase 2 data, and need for funding ahead of Phase 3 trials. Many predict a deal or partnership in Q1 2026.Sanofi (SNY): Frequently cited as a logical fit due to $ALT CEO Jerry Durso's 22-year history at Sanofi, which could facilitate a smooth integration. Speculation includes a "subsidiary model" acquisition (similar to Sanofi's Genzyme deal) to preserve $ALT's clinical momentum without big pharma bureaucracy. Sanofi has been active in metabolic disease deals.
0 · Reply
JuggernautRaider
JuggernautRaider Dec. 28 at 1:49 PM
$ALT top potential acquirers: 1. Eli Lilly (LLY) Best strategic fit. Lilly dominates obesity/metabolic disease and continues to invest aggressively to defend leadership. Pemvidutide’s dual GLP-1/glucagon mechanism and strong Phase 2b MASH data would complement Lilly’s incretin portfolio and extend reach into liver disease. 2. Novo Nordisk $NVO Clear incentive to neutralize emerging competition. Novo leads GLP-1s but lacks a differentiated MASH asset with antifibrotic signals. ALT would add pipeline depth and protect Novo’s long-term metabolic franchise. 3. Gilead Sciences $GILD Historically strong in liver disease and actively rebuilding growth. Pemvidutide’s MASH data directly aligns with Gilead’s strategic focus, and ALT’s market cap is easily digestible for GILD. 4. Pfizer $PFE Capital-rich and motivated to rebuild its post-COVID pipeline. Pfizer has publicly emphasized obesity and metabolic disease as priority areas, making ALT a logical bolt-on acquisition.
4 · Reply
gumby2196
gumby2196 Dec. 28 at 5:36 AM
$PFE is loosing the monthly 5 MAs again.
1 · Reply
reyofhope
reyofhope Dec. 28 at 5:03 AM
$PFE why are we trending?
1 · Reply
taxplanr
taxplanr Dec. 28 at 4:02 AM
DNA found in all C19 jabs $BNTX $MRNA $PFE https://www.instagram.com/reel/DSvhgVgEnE3/?igsh=MWcxcW11YzV4NmFwcQ==
0 · Reply
hegdaom
hegdaom Dec. 28 at 4:01 AM
$AGIO $LLY $PFE $MRK $CRSP
1 · Reply
taxplanr
taxplanr Dec. 28 at 3:52 AM
Complete investigation and accountability of the CDC $BNTX $MRNA $PFE https://www.instagram.com/p/DSu4_B3lZYS/?img_index=1&igsh=MWl6cWVyZTh1emNoOQ==
0 · Reply
ripztrip
ripztrip Dec. 28 at 12:47 AM
$AGIO $LLY $PFE $MRK $CRSP
1 · Reply
summer_of_the_small_caps
summer_of_the_small_caps Dec. 28 at 12:34 AM
$PFE Well if this vesper-3 data is bad we will be making a lower low beneath 20. This chart has still not bottomed and is making lower highs and lower lows. If the market sours in the new year that will not help matters either. And sub 20 - that dividend will be cut in half after successive failed acquisitions as the company goes into cash preservation mode given they have already cut things to the bone. Only then, will the board maybe ask Bourla to walk the plank. But all and all - PFE has been a poor investment long term under Bourla's guidance. I was really struggling to imagine what could drive this stock higher and it is quite sad that having the CEO resign might be the best driver of the share price. The CEO should have enough common sense and less hubris to step aside and do what is best for the company and probably his stock options.
1 · Reply
g_man_
g_man_ Dec. 28 at 12:18 AM
$PFE Getting paid to wait
0 · Reply
Northeast14
Northeast14 Dec. 27 at 12:52 PM
$PFE check out $GENFF this will be one to watch for 2026 https://genflowbio.com/
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 27 at 8:22 AM
🔎 $PFE Options Scan Update (02:22 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai
0 · Reply
PalladiumMidas19
PalladiumMidas19 Dec. 27 at 6:20 AM
$ELTP $JNJ $LIY.X $PFE Stop. We know you are both. Silly goose.
1 · Reply
Schube1255
Schube1255 Dec. 27 at 2:32 AM
$TRAW $PFE
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 27 at 2:18 AM
Enter: $PFE Calls Strike Price: $26 Expiry Date: JAN 16 2026 Buy in Price: $0.18 - $0.19 Sell Price: $0.29 Profit : +59% (Turn every $1 into $1.59) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
EmbraceVolatility
EmbraceVolatility Dec. 26 at 8:54 PM
$PFE Test of $26.50 coming in Jan. VESPER-3 trial data could send this over $27.50 like the surge on Oct 1st.
1 · Reply
Micheal_Pothead
Micheal_Pothead Dec. 26 at 8:51 PM
$PFE
0 · Reply
hegdaom
hegdaom Dec. 26 at 8:11 PM
$AGIO IMHO the pros outweigh the cons at these levels. $LLY $PFE $MRK $CRSP
1 · Reply
taxplanr
taxplanr Dec. 26 at 6:09 PM
C19 jabs Bioweapons Trial in the Netherlands $BNTX $MRNA $PFE https://sashalatypova.substack.com/p/my-testimony-for-the-case-in-the?utm_source=cross-post&publication_id=870364&post_id=175070275&utm_campaign=1021940&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply